Companies · Pharma

Strategic Pharmaceutical Solutions, Inc

Portland · Pharma · refined from filed group “Other Technology

Diligence memoA one-page analyst read on Strategic Pharmaceutical Solutions, Inc — recommendation, valuation, rhythm, risks.
$23.3M
Total raised · real
4
Rounds
0.8×
Latest step-up
Top 23%
Sector rank · raised
Series A
Latest stage · inferred · Fri Mar 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Strategic Pharmaceutical Solutions, Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.25× the median modeled value of Series A Pharma companies in 2016–2018 (14 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.3 yr ago; this sector typically re-raises about every 16 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Strategic Pharmaceutical Solutions, Inc is one of 310 Pharma companies tracked from Portland. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2018-03-02
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2010-04-08 Raised $10M (real) Modeled valuation $310M (est)$10M$310MSeries A2010Series A · 2015-10-16 Raised $10.0M (real) Modeled valuation $309M (est)$10.0M$309MSeries A2015Series A · 2016-05-16 Raised $1.9M (real) Modeled valuation $58M (est)$1.9M$58MSeries A2016Series A · 2018-03-02 Raised $1.5M (real) Modeled valuation $46M (est)$1.5M$46MSeries A2018+$10.0M+$1.9M+$1.5MCumulative $23M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$10.0M · 2010
Series A extension$10.0M · 2015
Series A extension$1.9M · 2016
Series A extension$1.5M · 2018

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$46.2M
Base estimate est.
$1.7M
Conservative case
$251.4M
Upside case
$6.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $309.7M · 2010-04-082010Series A · modeled $309.0M · 2015-10-16Series A · modeled $57.9M · 2016-05-16Series A · modeled $46.2M · 2018-03-022018
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
8.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
32 mo
Avg between rounds
$3.0M/yr
Capital velocity
16.2 yr
On record since
2010
First round
4
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.6× above median
This company$23.3M
Sector median$6.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.5M
Sector median$6.7M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$46.2M
Sector median$62.5M

Raised more than 78% of sector peers (real $). Modeled value above 55% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 14.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Qool Therapeutics, Inc. · Series A Raised $14.2M · modeled $432.4M (est)SpringWorks Therapeutics, LLC · Series A Raised $12.8M · modeled $396.9M (est)Caliber Therapeutics, Inc. · Series A Raised $12.0M · modeled $371.7M (est)Rodin Therapeutics, Inc. · Series A Raised $10.8M · modeled $335.3M (est)SmartPharm Therapeutics, Inc. · Series A Raised $10.5M · modeled $326.0M (est)AffyImmune Therapeutics, Inc. · Series A Raised $7.9M · modeled $243.4M (est)Silicon Therapeutics LLC · Series A Raised $6.5M · modeled $193.6M (est)Bold Therapeutics Inc. · Series A Raised $5.5M · modeled $169.6M (est)Geode Therapeutics Inc. · Series A Raised $5.3M · modeled $162.6M (est)Verseau Therapeutics, Inc. · Series A Raised $4.3M · modeled $133.2M (est)Constance Therapeutics, Inc. · Series A Raised $4.7M · modeled $131.6M (est)Colorado Therapeutics LLC · Series A Raised $6.9M · modeled $79.6M (est)Strategic Pharmaceutical Solutions, Inc (this company) Raised $23.3M · modeled $46.2M (est)Strategic Pharmaceutical Solutions, Inc
CompanyStageRaised · realValue · estvs peer med.
Qool Therapeutics, Inc.Series A$14.2M$432.4M2.38×
SpringWorks Therapeutics, LLCSeries A$12.8M$396.9M2.19×
Caliber Therapeutics, Inc.Series A$12.0M$371.7M2.05×
Rodin Therapeutics, Inc.Series A$10.8M$335.3M1.85×
SmartPharm Therapeutics, Inc.Series A$10.5M$326.0M1.80×
AffyImmune Therapeutics, Inc.Series A$7.9M$243.4M1.34×
Silicon Therapeutics LLCSeries A$6.5M$193.6M1.07×
Bold Therapeutics Inc.Series A$5.5M$169.6M0.93×
Geode Therapeutics Inc.Series A$5.3M$162.6M0.90×
Verseau Therapeutics, Inc.Series A$4.3M$133.2M0.73×
Constance Therapeutics, Inc.Series A$4.7M$131.6M0.72×
Colorado Therapeutics LLCSeries A$6.9M$79.6M0.44×
Strategic Pharmaceutical Solutions, Inc this companySeries A$23.3M$46.2M0.25×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$10.0M2010-04-08$45.5M$309.7M85%
Series A$10.0M2015-10-16$45.3M$309.0M85%
Series A$1.9M2016-05-16$8.5M$57.9M85%
Series A$1.5M2018-03-02$6.8M$46.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$10.0M2010-04-08
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series A$10.0M2015-10-16
    • Raised again after 66 mo — slower than the ~16 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  3. Series A$1.9M2016-05-16
    • Came back fast: 7 mo vs the ~16 mo sector norm.
    • Round 5.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  4. Series A$1.5M2018-03-02
    • Raised 22 mo later, in step with the ~16 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
Intelligence
2020 ~Q4
Modeled next raise · ~32mo cadence
$1.5M
Modeled next size est.range $1.5M$2.4M
0.8×
Last step-up
$3.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Scott Anderson11 other2015-10
Doug Jones2 other2018-03
Steve Fisher2 other2010-04
Bob Antin1 other2010-04
Doug Drew1 other2015-10
David Laurance2010-04
George Henriques2015-10
Greg Colvin2010-04
Jim Cleary2015-10
Kurt Green2015-10
Thomas Friar2010-04
Registry & provenance

Strategic Pharmaceutical Solutions, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1365077
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
C2 Therapeutics IncPharmaSeries A$25.9M$195.1Msame sector · same stage
Spiral Therapeutics IncPharmaSeries A$19.4M$120.6Msame sector · same stage
Solace Therapeutics IncPharmaSeries A$28.4M$202.2Msame sector · same stage
Time Therapeutics Inc.PharmaSeries A$28.6M$66.9Msame sector · same stage
ADvantage Therapeutics, Inc.PharmaSeries A$19.0M$111.4Msame sector · same stage
Rgenta Therapeutics, Inc.PharmaSeries A$18.9M$150.2Msame sector · same stage
Radiance Therapeutics, Inc.PharmaSeries A$18.7M$228.3Msame sector · same stage
Strata Oncology, Inc.PharmaSeries A$29.2M$27.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Strategikon Pharma, Inc.PharmaSeed$7.0M85%
Pharmaceutical Resource Technology, Inc.PharmaceuticalsSeries A$37.5M83%
Pike Therapeutics Inc.PharmaPre-Seed$751K82%
PharmaCCX, Inc.Biotech / PharmaSeries A$45.1M82%
Guide Therapeutics, Inc.PharmaSeries A$173.6M81%
Comet Therapeutics, Inc.PharmaSeries A$435.3M81%
Pharma Acuity, Inc.PharmaPre-Seed$3.9M81%
Avery Therapeutics, Inc.PharmaPre-Seed$23.7M81%
Frequently asked
How much funding has Strategic Pharmaceutical Solutions, Inc raised?
Strategic Pharmaceutical Solutions, Inc has raised approximately $23.3M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Strategic Pharmaceutical Solutions, Inc's estimated valuation?
Provath's modeled valuation for Strategic Pharmaceutical Solutions, Inc is approximately $46.2M (modeled range $1.7M–$251.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Strategic Pharmaceutical Solutions, Inc at?
Strategic Pharmaceutical Solutions, Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Mar 02.
What does Strategic Pharmaceutical Solutions, Inc do and where is it based?
Strategic Pharmaceutical Solutions, Inc operates in the Pharma sector, based in Portland.
Explore related

See where Strategic Pharmaceutical Solutions, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Strategic Pharmaceutical Solutions, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.